Ultragenyx Pharmaceutical Inc.
RARE
Market Cap$3.51B
Close$
$55.30
49% upside
Current Fair Value
49% upsideUndervalued by 49% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.51 Billion |
|---|---|
| Enterprise Value | $3.42 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-6.29 |
| Beta | 0.24 |
| Outstanding Shares | 96,288,650 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -6.51 |
|---|---|
| PEG | 56.65 |
| Price to Sales | 6.19 |
| Price to Book Ratio | 37.12 |
| Enterprise Value to Revenue | 5.79 |
| Enterprise Value to EBIT | -6.71 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.27 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Ultragenyx Pharmaceutical Inc.
CEO: Emil Kakkis